Retour
  1. Accueil
  2. Profil de Aline Genbauffe (UMONS)
Profil

Genbauffe Aline

Université de Mons - UMONS > Faculté de Médecine et de Pharmacie > Service de Biologie humaine et Toxicologie

Université de Mons - UMONS > Recherche > Service de l'Institut des Sciences et Technologies de la santé

Principaux co-auteurs référencés
BLANKERT, Bertrand  (2)
JOURNE, Fabrice  (2)
Soumoy, Laura  (2)
WELLS, Mathilde  (2)
BEUKENS, Delphine  (1)
Principaux mots-clés référencés
Bufalin (2); ATP1A1 (1); Cancer Research (1); Cardiotonic steroid (1); Clinical Trial (1);
Principales disciplines référencées
Oncologie (2)
Chimie (2)
Physique, chimie, mathématiques & sciences de la terre: Multidisciplinaire, généralités & autres (1)

Publications (3)

La plus téléchargée
52 téléchargements
Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y https://hdl.handle.net/20.500.12907/48079

La plus citée

4 citations (Scopus®)

Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y https://hdl.handle.net/20.500.12907/48079

Wells, M., Hervé Alexandre, Tiflit Abdellah, Konare Djabou, Beukens, D., Genbauffe, A., Zubrzycki Sandrine, Fougère Laetitia, Michel Thomas, Blankert, B., & Destandau Emilie. (16 June 2025). Bio-guided fractionation strategy by centrifugal partition chromatography to reveal the bioactive potential of toad venom extracts [Poster presentation]. 54th International Symposium on High Performance Liquid Phase Separations & Related Techniques, Bruges, Belgium.
Peer reviewed

Genbauffe, A., Soumoy, L., Lefranc, F., & Journe, F. (September 2024). Reviewing Clinical Trials and Meta-Analyses to Assess the Efficacy and Safety of Huachansu in Cancer Treatment. Journal of Biomedical Research & Environmental Sciences, 5 (9), 1132-1139. doi:10.37871/jbres2001
Peer reviewed

Soumoy, L., Genbauffe, A., Mouchart, L., Sperone, A., Trelcat, A., Mukeba-Harchies, L., Wells, M., Blankert, B., Najem, A., Ghanem, G., Saussez, S., & Journe, F. (04 January 2024). ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy. Cancer Cell International, 24 (1), 8. doi:10.1186/s12935-023-03196-y
Peer reviewed vérifié par ORBi

Contacter ORBi UMONS